Answers are grounded in this paper and cite their sources.
In terms of hematologic and cytogenetic responses, tolerability, and the likelihood of progression to accelerated-phase or blast-crisis CML, imatinib was superior to interferon alfa plus low-dose cytarabine as first-line therapy in newly diagnosed chronic-phase CML.
No takes yet. Share an insight, caveat, or question.
O’Brien et al. (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: